Detecting familial hypercholesterolemia: An observational study leveraging mandatory universal pediatric total cholesterol screening in Slovakia.

Branislav Vohnout, Katarina Raslova, Tomas Freiberger, Ian Bridges, Marie Zachlederova, Viera Donicova, Katarina Gonova, Alexander Klabnik, Lukas Tichy, Dagmar Buckova

Journal: Journal of clinical lipidology 2024;18(4):e537-e547

PMID: 38955586

Abstract

BACKGROUND

In Slovakia, a mandatory national universal pediatric total cholesterol (TC) screening program is in place to identify cases of familial hypercholesterolemia (FH). However, the program's effectiveness has not been systematically assessed.

OBJECTIVE

This study aimed to estimate the prevalence of FH among parents of children that had elevated TC levels identified during screening.

METHODS

This prospective, non-interventional, observational study enrolled parents of 11-year-old children who underwent TC screening in 23 selected pediatric outpatient clinics between 2017 and 2018. FH was diagnosed using the Dutch Lipid Clinic Network (DLCN) criteria and targeted next-generation sequencing. The primary objective was to estimate the proportion of children with a TC level of >188 mg/dL (>4.85 mmol/L) who had a parent with a confirmed diagnosis of FH.

RESULTS

A total of 112 parents of 56 children with an elevated TC level were enrolled. Five children (8.9%) had a parent in whom FH was genetically confirmed. Without genetic analysis, all five parents would only be diagnosed with "possible FH" by DLCN criteria. Of parents, 83.9% (n = 94/112) had an low-density lipoprotein cholesterol (LDL-C) level of >116 mg/dL (>3 mmol/L), but only 5.3% (n = 5/94) received lipid-lowering therapy. Among the five parents with genetically confirmed FH, all had an LDL-C level >116 mg/dL (>3 mmol/L), with a mean (±SD) of 191 (±24) mg/dL (4.94 [±0.61] mmol/L). Only two of these parents received lipid-lowering therapy.

CONCLUSIONS

The present study demonstrates the significance of mandatory universal pediatric TC screening in identifying families with FH and other at-risk families in need of lipid-lowering therapy.

Copyright © 2024. Published by Elsevier Inc.

Address: Metabolic Center, Ltd, Coordination for Familial Hyperlipidemias, Slovak Medical University, Bratislava, Slovakia (Dr Raslova). Electronic address: [email protected].; Outpatient Department of Internal Medicine and Diabetology, Košice, Slovakia (Dr Donicova).; Internal Outpatient Clinic, MedPed Lipid Clinic, Piestany, Slovakia (Dr Gonova); Faculty of Public Health, Slovak Medical University, Bratislava, Slovakia (Dr Gonova).; Cardiology Outpatient Clinic, MedPed Lipid Clinic, Namestovo, Slovakia (Dr Klabnik).; Centre of Molecular Biology and Genetics, Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic (Dr Tichy); Medical Faculty, Masaryk University, Brno, Czech Republic (Drs Tichy and Freiberger).; Amgen UK Ltd, Uxbridge, United Kingdom (Dr Bridges).; Amgen Slovakia s.r.o., Bratislava, Slovakia (Dr Buckova).; Amgen Czech Republic s.r.o., Prague, Czech Republic (Dr Zachlederova).; Medical Faculty, Masaryk University, Brno, Czech Republic (Drs Tichy and Freiberger); Centre of Cardiovascular Surgery and Transplantation, Brno, Czech Republic (Dr Freiberger). Electronic address: [email protected].; Diabetes and Lipid Outpatient Clinic, Diabeda s.r.o., Bratislava, Slovakia (Dr Vohnout); Coordination Center for Familial Hyperlipidemias, Institute of Nutrition, Department of Diabetes, Slovak Medical University, Bratislava, Slovakia (Dr Vohnout); Department of Epidemiology, School of Medicine, Comenius University, Bratislava, Slovakia (Dr Vohnout). Electronic address: [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.